Aradigm Corporation, incorporated on January 30, 1991, is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. It is focused on commercializing its products in the United States, European Union (EU), Japan and China. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. The Company offers AERx pulmonary drug delivery platform and other technologies. The Company's partnered programs under development include Inhaled Ciprofloxacin. The Company is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). The Company is focused on inhaled nicotine product utilizing its AERx delivery system that is focused on addressing the acute craving for cigarettes and, through gradual reduction of the peak nicotine levels, could wean-off patients from cigarette smoking and from the nicotine addiction. ...
+See More2019-03-23 09:31:00 Saturday ET

Congresswoman Alexandria Ocasio-Cortez proposes greater public debt finance with minimal tax increases for the Green New Deal. In accordance with the modern
2017-03-09 05:32:00 Thursday ET

From 1927 to 2017, the U.S. stock market has delivered a hefty average return of about 11% per annum. The U.S. average stock market return is high in stark
2019-03-15 13:36:00 Friday ET

CNBC stock host Jim Cramer recommends both Caterpillar and Home Depot as the U.S. bull market is likely to continue in light of the recent Fed Chair comment
2018-09-11 18:36:00 Tuesday ET

President Trump tweets that Apple can avoid tariff consequences by shifting its primary supply chain from China to America. These Trump tariffs on another $
2018-03-27 07:33:00 Tuesday ET

CNBC's business anchorwoman Becky Quick interviews Nobel Laureate Joseph Stiglitz on the current trade war between America and China. As America imposes
2018-05-04 06:29:00 Friday ET

Commerce Secretary Wilbur Ross suggests that 5G remains a U.S. top technology priority in light of the telecom merger proposal between Sprint and T-Mobile a